A Simple Pill Could Prevent Sight Loss in Diabetes-Driven Eye Condition, Early Findings Suggest
In a 24-patient trial, 55% showed early biological activity, and researchers said the pill could offer a non-invasive alternative to eye injections.
4 Articles
4 Articles
A recent study has shown that oral medication may help to reduce visual damage to people with non-reproductive diabetic retinas, thus opening the way for the development of less intrusive treatment options in the early stages of the disease.
Oral Drug Shows Promise in Protecting Against Diabetic Eye Disease
An investigational drug could offer a new way to prevent or slow vision-threatening damage caused by diabetic retinopathy. Results published today in Science Translational Medicine show promise for danegaptide, an oral small molecule drug designed to protect the blood vessels of the retina from damage caused by high blood glucose, offering a simpler alternative to current medication. “Managing diabetic eye disease before irreversible damage occu…
A simple pill could prevent sight loss in diabetes-driven eye condition, early findings suggest
Researchers at Trinity College Dublin, in collaboration with Breye Therapeutics, have found that an oral medication ("Danegaptide") can protect against vision-threatening damage in nonproliferative diabetic retinopathy (NPDR), a leading cause of blindness in working-age adults.
Breye Therapeutics has a paper on its oral danegaptide treatment for patients with NPDR published in Science Translational Medicine
Oral treatment danegaptide represents “a potential paradigm shift” toward earlier, non-invasive treatment of Non-Proliferative Diabetic Retinopathy (NPDR), say authors Study “provides compelling evidence” that danegaptide robustly protects inner blood-retina barrier (iBRB), while also dampening VEGF-associated activity This “dual approach”, and its ability to be used earlier, “may translate into improved outcomes” Breye is now planning […]
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
